News Travere claims first FDA OK in rare kidney disease FSGS Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.
News Boehringer drug scores in rare kidney disease FSGS Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.
News Clock starts ticking on UK's single patient record plan In today's King's Speech, the UK government unveiled the NHS Modernisation Bill, starting the process of introducing a single patient record.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.